Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch

Nabriva Therapeutics PLC has been preparing for two years to launch Xenleta (lefamulin), which the US Food and Drug Administration approved as an intravenous and oral treatment for community-acquired bacterial pneumonia (CABP) on 19 August. The company believes that it has laid the groundwork for a successful launch at a time when reimbursement for antibiotics finally may be moving in a positive direction, though there still is some skepticism about commercial prospects.

Nabriva's 60 sales representatives initially will target about 900 hospital and health care system accounts where physicians are looking to...